Rexulti Tablet
Product Images NDC 59148-035

Product Visual Gallery

This gallery contains 19 technical images submitted to the FDA as part of the official labeling for Rexulti (NDC 59148-035). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Otsuka America Pharmaceutical, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Rexulti 025mg Bottle Label

FDA Label Image

Rexulti 025mg Carton

FDA Label Image

Rexulti 05mg Bottle Label

FDA Label Image

Rexulti 05mg Carton

FDA Label Image

Rexulti 1mg Bottle Label

FDA Label Image

Rexulti 1mg Carton

This text seems to be a description of a medication called "REXULTI." It includes the tablet size (30 tablets) and the national drug code (NDC 59145-037-13). The medication contains brexpiprazole, which is a type of drug used to treat certain mental illnesses. The rest of the text appears to be gibberish or random letters/words and cannot be understood.*

FDA Label Image

Rexulti 2mg Bottle Label

FDA Label Image

Rexulti 2mg Carton

The text appears to be a mix of random letters, symbols, and numbers. There is no readable description available.*

FDA Label Image

Rexulti 3mg Bottle Label

FDA Label Image

Rexulti 3mg Carton

REXULTI is a prescription medication containing 30 tablets of Brexpiprazole, used for treating certain mental disorders. The tablets are white, oval-shaped, with NDC code 5914303913 or 5914803913. The medication guide outlines the uses, dosage, and possible side effects. It is essential to consult a physician before taking the medication.*

FDA Label Image

Rexulti 4mg Bottle Label

FDA Label Image

Rexulti 4mg Carton

FDA Label Image

Rexulti Chem Structure

FDA Label Image

Rexulti Figure 01

This appears to be a report on Brexpiprazole PK, with information related to measures of Fold Change, 90% confidence intervals, and impairment of renal and hepatic systems. It also includes population descriptions based on gender and age, as well as a chart showing changes relative to reference.*

FDA Label Image

Rexulti Figure 02

Brexpiprazole PK was analyzed for its change due to measures fold change and 90% confidence intervals caused by different inhibitors and inducers of CYP enzymes, such as CYP3A4 inhibitor Crmex, CYP2D6 inhibitor Cmex1o, CYP3A4 Inducer Crmex-, CYP2BS inhibitor Cmax, Gastric PH increase caused by Omeprazole, and others. The change was observed relative to the reference (without interacting drug).*

FDA Label Image

Rexulti Figure 03

This text appears to be a chart showing the effect of certain substances on various substrates and analytes. It includes the substrates Dextromethorphan, Fexofenadine, Bupropion, Lovastatin, and Roswastatin and notes their PK fold changes and confidence intervals for measurements of analytes in urine. Without more context, it is unclear what the purpose of this information is or how it might be used.*

FDA Label Image

Rexulti Figure 04

FDA Label Image

Rexulti Figure 05

FDA Label Image

Rexulti Figure 06

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.